PPARG and breast carcinoma: Similarly, treatment with 2 μM γ-tocotrienol, 3.2 μM rosiglitazone, or 3.2 μM GW9662 alone or in combination had little or no effect on PPRE mediated activity in vehicle-treated or scrambled RNA transfected PPARγ positive MCF-7 (Figure 8(c)) and MDA-MB-231 (Figure 8(d)) breast cancer cells and no significant effect on downregulated PPARγ levels in PPARγ siRNA transfected MCF-7 (Figure 8(c)) and MDA-MB-231 (Figure 8(d)) breast cancer cells.